All News

guidelines.jpg (keep)

British Society of Rheumatology Plans Revision of Systemic Sclerosis Guideline

d Jack Cush, MD

British Society for Rheumatology (BSR) last published its guideline for systemic sclerosis (SSc) in 2016. Given the many advances in the field the BSR has outlined their plans to update the management of SSc.

Read Article
warning, caution

EMA Final Update on JAK Inhibitors and MACE, Malignancy & VTE Risks

d Jack Cush, MD

The EMA has updated recommendations regarding the use of JAK inhibitors by issuing a direct healthcare professional communication summarizing the data and warnings regarding an increased risk of malignancy, major adverse cardiovascular events (MACE), serious infections, VTE, and mortality in some patients receiving JAKi for the treatment of chronic inflammatory disorders.

Read Article
XX Factor Women in Rheumatology

The Origin Story of RheumNow’s Campaign: Women in Rheumatology--The XX Factor

d Kathryn H. Dao, M.D.,  , Rachel Tate, DO

Origin stories have captivated me ever since my childhood spent reading Greek Mythology and Marvel comic books. Superheroes have different powers and personalities.

Read Article
Among 182 adult #RA pts - half (50%) had Depression and 25% had anxiety. Patients with depression or anxiety had higher HAQ and DAS28 scores. Depression was more prevalent in females, housewives, & low education. Anxiety more in blue-collar workers https://t.co/C9Foulu29l https://t.co/tcCaV85kU0

Links:

Dr. John Cush RheumNow ( View Tweet)
Paxlovid (Nirmatrelvir-Ritonavir) should be used w/in 5d of COVID Sxs onset. Drug interactions include: steroids, anticoagulants (Eliquis, Xarelto, warfarin), Flomax, Calcium channel blockers, benzodiazepines. https://t.co/VZpS1z3OGR https://t.co/hR6JAJ3BBO

Links:

Dr. John Cush RheumNow ( View Tweet)
Atopic Disease Increases Osteoarthritis Risk Analysis of commercial insurance claims suggests that patients with asthma or atopic dermatitis have a significantly increased risk of osteoarthritis (OA). https://t.co/450DnhOfY5 https://t.co/zUfD4jhumY

Links:

Dr. John Cush RheumNow ( View Tweet)
Frunevetmab (Solensia), is a cat-specific mAb against nerve growth factor was FDA approved, for use in CATS, to treat the pain of osteoarthritis. CATS! https://t.co/vY0CCMjZmC https://t.co/UnpDpo5fyB

Links:

Dr. John Cush RheumNow ( View Tweet)
Tomorrow! Join us for Tuesday Night Rheumatology. Our panelists will discuss the challenges they have faced trying to manage a career and family life, as well as provide advice and strategies for managing competing priorities and obligations. https://t.co/OlP0pupkMV https://t.co/pZQMASafcG

Links:

Dr. John Cush RheumNow ( View Tweet)
Abbvie has completed a phase II upadacitinib vs combo elsubrutinib/upadacitinib ( ABBV-599) in active #SLE - M19-130 (SLEek) Phase 2 trial met the primary endpoint SRI-4 response and pred dose<=10 mg qd. No new safety signals - Phase III trial planned https://t.co/6CwS2AVamH https://t.co/b4wQ6IoiOz

Links:

Dr. John Cush RheumNow ( View Tweet)
Gender Gap in Editors. Cross-sect study of top 10 Intl medical journals in 41 categories shows women underrepresented as editors in chief. Women editors=21%. No women editors in dentistry, oral surgery; allergy, psychiatry; anesthesiology; ophthalmology https://t.co/JWAwrO9F4w https://t.co/0viEMa6ImK

Links:

Dr. John Cush RheumNow ( View Tweet)
Variability in rheumatologist steroid prescribing - using data on ~500k RA pts and 6,875 rheumatologists. Those LESS likely to prescribe alot of steroids were: women, solo practitioners, in practice ≥10 years, seeing greater#s of RA pts/year https://t.co/ELk0avorOe

Links:

Dr. John Cush RheumNow ( View Tweet)

Open-label Trial of 14 pts with MAS due to steroid refractory systemic JIA or adult-onset Still’s demonstrated the efficacy of IV emapalumab, an anti-IFNγ mAb. Demonstrated signif reductions in LDH, sIL-2R, Ferritin, CXCL9, & steroid dose https://t.co/vgxT5KzmQF https://t.co/gDLmfOlSHG

Links:

Dr. John Cush RheumNow ( View Tweet)
Mom in Medicine BINGO - Just try to Win! #WIR https://t.co/Mb4KtsWQPK

Links:

Dr. John Cush RheumNow ( View Tweet)

LAVLI - A New Autoinflammatory Disorder NIH researchers have have described a novel autoinflammatory disorder called "Lyn kinase-associated vasculopathy and liver fibrosis" (LAVLI), based on a mutation in the LYN gene. https://t.co/RYmb3QFB1T https://t.co/sn5hwVxwPk

Links:

Dr. John Cush RheumNow ( View Tweet)
2022 EULAR Recommendations for ANCA-associated Vasculitis EULAR has published the 2022 update on recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). https://t.co/lvPO26S0k6 https://t.co/cQtiEctrTR

Links:

Dr. John Cush RheumNow ( View Tweet)
30 consecutive seropositive (CCP or RF+) early RA pts - 60% had pulmonary abnormalities (PA). PA correlated with presence of neutrophil activation, parameters of inflammation and RF titres. https://t.co/dsbjPhuYzf https://t.co/1Zmyqjuaxj

Links:

Dr. John Cush RheumNow ( View Tweet)
Autoimmune-Rheum Dz (AIRD) flares occur in 10% w/ COVID vaccination, esp in pts w/ comorbidities, autoimmune morbidities & mental health disorders & Moderna vaccine. 3453 AIRD pts who recv Vax 9.5-11.3% had clinical flares (Arthritis 62% & fatigue 59%) https://t.co/C0WA2Znixl https://t.co/vXzL8XR7kd

Links:

Dr. John Cush RheumNow ( View Tweet)
Tofacitinib May Reduce Interstitial Lung Disease Risk in RA Tofacitinib (Xeljanz) in patients with RA stood out among several other biologic and targeted sDMARDs when it came to the incidence of ILD, a retrospective cohort study showed. https://t.co/2DCn53Rk4z https://t.co/sZYhgfCU0E

Links:

Dr. John Cush RheumNow ( View Tweet)
Intrathecal Methotrexate for Cerebritis Dr. Jack Cush reviews the CV advantage to walking, the OA risk with running and the eczema-OA connection; these articles and journal reports from the past week on RheumNow. https://t.co/wTOehtaU27 https://t.co/8Xp0C6tqBe

Links:

Dr. John Cush RheumNow ( View Tweet)
Join RheumNow during the month of April as we discuss Women in Rheumatology, the XX Factor. Sign up to attend our series! https://t.co/e3AJKwnoWs https://t.co/cpUmsOVuAT

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×